Covid: Wittum (AstraZeneca), ‘no restyling, only given a name to vaccine’

Milan, March 31 (beraking latest news Salute) – “I agree: the name is quite complicated”. This, however, “is no restyling operation. The process of defining a drug name is completely different from the approval process. They are two processes that go in parallel”. The process of defining the name “has finished these days and we have communicated the name of our vaccine“. This was stated by Lorenzo Wittum, CEO of AstraZeneca Italia, talking about the name of the anti-Covid vaccine produced by the Anglo-Swedish giant (Vaxzevria), today during a webinar promoted by the American Chamber of Commerce in Italy (AmCham).